Scientists found that women’s brains respond to Alzheimer’s risk factors dramatically differently than men’s and the medical system has been measuring the wrong thing

Two thirds of all Alzheimer’s patients are women. For decades, the standard explanation for this has been longevity: women live longer than men, and Alzheimer’s is a disease of old age, so the numbers follow naturally. A study published in Biology of Sex Differences on May 19, 2026 by researchers at UC San Diego has now put significant pressure on that explanation. The longevity gap does not account for what they found. The same risk factors that cause cognitive decline in both sexes are hitting women’s brains considerably harder, and the medical system has been evaluating both sexes against the same thresholds as though that were not true.

The study analyzed data from 17,182 adults aged 40 and older drawn from the Health and Retirement Study, one of the largest and most representative datasets on aging in the United States. What the researchers found was not that women have more risk factors, though in many cases they do. It was that the same risk factor, at the same level of severity, produces greater cognitive damage in a woman’s brain than in a man’s.

The Risk Factors That Hit Harder in Women

The UC San Diego team, led by Megan Fitzhugh and senior author Judy Pa, examined 13 established modifiable dementia risk factors across the full dataset. Women showed higher rates of seven modifiable risk factors including depression, physical inactivity, smoking, poor sleep and elevated cholesterol. But higher prevalence was not the finding that changes clinical practice. The finding that matters is what happened when the researchers looked at impact rather than prevalence.

Depression showed the largest sex-specific difference in the entire analysis. In women, depression was associated with significantly greater cognitive impairment than the same level of depression in men. The relationship between depressive symptoms and declining memory, executive function, and processing speed was meaningfully stronger in female participants across every cognitive domain measured.

Physical inactivity showed a similar pattern. A sedentary woman and a sedentary man are not carrying equivalent cognitive risk, even when their activity levels, ages, and other health markers are identical. The inactive woman’s brain is paying a higher price for the same behavior.

“Looking beyond which risk factors are most common, we found that some have a disproportionately larger impact on women’s cognition,” said Fitzhugh. “This suggests that prevention efforts may be more effective if they are tailored not just to risk factor prevalence, but to how strongly each factor affects cognition in women versus men.”

Why the Same Risk Factor Produces Different Damage

The biological reasons behind this disparity are not fully settled, but several converging lines of research point toward mechanisms that are specific to female brain biology.

Neuroinflammation is one of the central candidates. Women generally experience stronger inflammatory responses than men, and Alzheimer’s is associated with inflammation in the brain. When a risk factor like depression or physical inactivity generates systemic inflammation, a brain that mounts a stronger inflammatory response to begin with will sustain more inflammatory damage from the same trigger. The female immune system, which has known differences from the male immune system in how it responds to chronic stressors, may be amplifying the neurological consequences of risk factors that appear similar on paper.

The tau protein story adds another layer. Previous research has shown that once women develop elevated tau levels, they often experience faster cognitive decline than men with equivalent levels of tau. This means the female brain is not just more vulnerable to developing Alzheimer’s pathology. Once that pathology begins, it progresses more aggressively. The same tau burden produces worse outcomes in women than in men, which means the thresholds used to define concerning tau levels in clinical settings may be calibrated too loosely for female patients.

Hormonal factors compound this picture significantly. Estrogen has known neuroprotective effects, and the hormonal changes of menopause represent a withdrawal of that protection at precisely the age when Alzheimer’s risk begins climbing. The Women: Inflammation and Tau Study at UC San Diego is specifically investigating how the loss of estrogen at menopause interacts with neuroinflammation and tau accumulation, and preliminary findings suggest the hormonal transition is a critical vulnerability window that the standard risk assessment framework does not explicitly account for.

The Blood Test Finding That Should Change Screening

A separate UC San Diego study published in JAMA Network Open in March 2026 extended this picture into early detection in a way that has direct clinical implications. Researchers found that a blood-based biomarker called phosphorylated tau 217, or p-tau217, can predict a woman’s risk of developing dementia as many as 25 years before symptoms appear.

Higher p-tau217 levels were more strongly associated with poorer cognitive outcomes among women over age 70 than those younger than 70, and among those with the APOE ε4 genetic risk factor for Alzheimer’s disease. The predictive power of this biomarker was also stronger in women who had received estrogen plus progestin hormone therapy, adding another layer of evidence that hormonal biology is modifying how Alzheimer’s pathology develops and expresses in female brains.

The practical implication is that a blood test already in development could identify women at elevated dementia risk decades before any cognitive symptom appears, providing a window for intervention that does not currently exist in standard clinical practice. The test exists. The question is whether the medical system will apply it with the sex-specific thresholds the biology actually requires, or continue using the same cutoffs for both sexes.

What the Standard Framework Has Been Missing

The broader critique embedded in this body of research is one that senior author Judy Pa articulated directly. “Sex differences are profoundly overlooked among many leading causes of death like Alzheimer’s, heart disease and cancer.”

Most clinical risk calculators for dementia do not apply sex-differentiated weights to individual risk factors. A woman’s depression score and a man’s depression score contribute equally to their assessed risk. Their physical activity levels are evaluated against the same benchmarks. Their tau levels are flagged at the same thresholds. The UC San Diego data shows that this approach is systematically underestimating risk in women, because the assumption that equal risk factor burden means equal cognitive vulnerability turns out to be wrong.

This has consequences that extend beyond individual patients. Population-level dementia prevention programs designed around risk factor targets that were derived from mixed-sex or male-dominant datasets will naturally underserve women, because the intervention thresholds they use were not calibrated for female brain biology. A woman whose depression is being adequately treated by male-population standards may still be experiencing a level of depressive symptomatology that is doing disproportionate damage to her cognitive trajectory.

“Ultimately, a more nuanced understanding of these differences could help us design smarter, more targeted interventions,” Fitzhugh said.

The Lifetime Risk Number Nobody Tells Women

The data point that puts all of this in its starkest context is the lifetime risk figure. The overall lifetime risk of acquiring Alzheimer’s for individuals aged 65 is 21.2% for females and 11.6% for males. A 65-year-old woman is nearly twice as likely to develop Alzheimer’s as a 65-year-old man, and longevity alone does not explain the gap. Yet the conversations most women have with their doctors about dementia prevention use the same framework, the same thresholds, and the same intervention priorities as the conversations men have.

The UC San Diego research is not the first to document sex differences in Alzheimer’s risk, but it is among the most comprehensive attempts to quantify exactly where those differences sit and how large they are across a nationally representative population. The finding that depression, physical inactivity, and several other modifiable risk factors carry a heavier cognitive penalty for women than for men is actionable information that should change how prevention is prioritized, how early detection is timed, and how clinical thresholds are set for female patients.

The medical system built its Alzheimer’s risk framework on data that treated sex as a covariate to control for rather than a variable that fundamentally changes the biological relationship between risk and outcome. For the two thirds of Alzheimer’s patients who are women, that framework has been measuring the wrong thing.

Source:

Fitzhugh, M., Pa, J., et al. Sex differences in modifiable risk factors of dementia and their associations with cognition. Biology of Sex Differences, May 19, 2026. DOI: 10.1186/s13293-026-00692-2 https://today.ucsd.edu/story/sex-differences-in-dementia-risks-reveal-stronger-cognitive-impacts-in-women

Shadyab, A.H., et al. Blood Test Predicts Dementia in Women as Many as 25 Years Before Symptoms Begin. JAMA Network Open, March 10, 2026. https://today.ucsd.edu/story/blood-test-predicts-dementia-in-women-as-many-as-25-years-before-symptoms-begin